Eikon Therapeutics priced an upsized initial public offering that raised roughly $381 million to fund clinical development of its oncology-focused programs. The company, built around super-resolution microscopy and a portfolio that includes TLR7/8 co-agonist EIK-1001 and PARP inhibitors, said proceeds will prioritize advancing multiple candidates through mid- and late-stage trials. Eikon’s debut comes amid a brisk week for life‑science listings, signaling renewed investor appetite for seasoned drug developers with late-stage assets. Agomab Therapeutics and SpyGlass Pharma followed with their own Nasdaq listings, collectively raising about $350 million. Agomab will fund immunology programs while SpyGlass focuses on long‑acting ocular therapies; both IPOs reflect increasing investor willingness to back specialized clinical-stage biotechs. The recent issuance cadence—anchored by large, upsized offerings—could ease access to public capital for other well‑capitalized drug developers this year.